Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Fuji
Baxter
Chinese Patent Office
Farmers Insurance
McKesson
Queensland Health
Merck

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,239,180

« Back to Dashboard

Which drugs does patent 6,239,180 protect, and when does it expire?

Patent 6,239,180 protects QUTENZA and is included in one NDA.

This patent has twelve patent family members in ten countries.
Summary for Patent: 6,239,180
Title: Transdermal therapeutic device and method with capsaicin and capsaicin analogs
Abstract:Transdermal application of capsaicin (or a capsaicin analog) in a concentration from greater than about 5% to about 10% by weight has been discovered to be an extremely effective therapy for treating neuropathic pain, so long as an anesthetic, preferably by means of a transdermal patch, is administered initially to the affected area to minimize the expected side effects from subsequent capsaicin application.
Inventor(s): Robbins; Wendye R. (San Mateo, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:08/990,633
Patent Claim Types:
see list of patent claims
Use; Device; Formulation; Delivery;

Drugs Protected by US Patent 6,239,180

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Acorda QUTENZA capsaicin PATCH;TOPICAL 022395-001 Nov 16, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,239,180

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,248,788 Therapeutic method with capsaicin and capasicin analogs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,239,180

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 240723 ➤ Try a Free Trial
Austria 344023 ➤ Try a Free Trial
Canada 2314326 ➤ Try a Free Trial
Cyprus 1107582 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Argus Health
Boehringer Ingelheim
Baxter
Chinese Patent Office
Johnson and Johnson
Daiichi Sankyo
UBS
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.